Art

J-GLOBAL ID：201902254248815948   Reference number：19A1369294

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis

胃癌に対する抗PD-1抗体療法後の化学療法の有効性と安全性:硬化性胆管炎の症例

Author (13)： Kono Masashi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Sakurai Toshiharu (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Okamoto Kazuki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Masaki Shou (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Nagai Tomoyuki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Komeda Yoriaki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Kamata Ken (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Minaga Kosuke (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Yamao Kentarou (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Takenaka Mamoru (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Watanabe Tomohiro (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Nishida Naoshi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Kudo Masatoshi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 58  Issue： 9  Page： 1263-1266(J-STAGE)  Publication year： 2019 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： PD-1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1369294&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： ramucirumab ,  nab-paclitaxel ,  nivolumab ,  immune checkpoint ,  cholecystitis

JST classification (3)： Clinical oncology in general  (GE03010Y) ,  Tumors(=neoplasms)of digestive system  (GH04000D) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (23)：

• 1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.
• 2. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872, 2007.
• 3. Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 49, 2017.
• 4. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 44: 1063-1074, 2006.
• 5. Kulaksiz H, Heuberger D, Engler S. et al. Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 40: 214-218, 2008.

Terms in the title (8)： 胃癌 ,  抗PD-1抗体 ,  療法 ,  化学療法 ,  有効性 ,  安全性 ,  硬化性胆管炎 ,  症例